- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01509651
Sugammadex and Heart Failure
Reversal of Rocuronium-induced Neuromuscular Block With Sugammadex in Heart Failure Patients
Although anticholinesterase reversal agents have been used in combination with anticholinergic drugs for over half a century, it has been suggested that they should be used with caution in patients with underlying cardiovascular disease. As sugammadex has no endogenous targets, it is unlikely to cause any adverse cardiovascular effects. This selective relaxant binding agent is specifically designed to encapsulate rocuronium, which can, therefore, promptly restore neuromuscular function regardless of any levels of NMB as the dose is increased.
Some reports, however, suggest that sugammadex may have increased time to effect in some patient populations like the elderly, patients in intensive care and renal failure patients. A less dynamic circulation and increased transfer time to the effector site in these subjects are likely explanations for this effect. The present trial was designed to assess the safety and efficacy of sugammadex 2.0 mg kg-1 for the reversal of rocuronium-induced NMB in patients with heart failure.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Aalst, Belgien, 9300
- OLV Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- aged 18 yr or older
- categorized as American Society of Anesthesiologists class 3-4 and New York Heart Association class 2-4
- with an ejection fraction <25%
- scheduled to undergo elective surgery for cardiac resynchronization therapy, an automated implantable cardioverter-defibrillator (ICD), or battery replacement of an ICD or biventricular pacemaker, during general anaesthesia.
Exclusion Criteria:
- expected to have a difficult intubation for anatomic reasons
- they had a neuromuscular disorder
- a personal or family history of malignant hyperthermia
- or known allergy to medication used during general anaesthesia
- not able or willing to give written informed consent.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Sugammadex
|
After the induction of anaesthesia, monitoring neuromuscular function is initiated and performed continuously using the TOF-Watch SX (Organon Ireland Ltd, Ireland) at the thumb.
Repetitive train-of four (TOF) stimulation is applied every 15 s at the ulnar nerve until the end of anaesthesia, at least until recovery of the TOF ratio to 0.9 after administration of sugammadex.
Each patient receives a single IV bolus dose of rocuronium 0.6 mg kg-1, after which tracheal intubation is performed.
Maintenance doses of rocuronium 0.1 mg kg-1, are permitted as required and administered at the reappearance of the second twitch in the TOF.
On reappearance of the second twitch at the end of surgery, patients receive a single IV bolus dose of sugammadex, 2.0 mg kg-1, for reversal.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
The time from start of sugammadex administration to recovery of the train-of-four (TOF) ratio to 0.9.
Zeitfenster: Participants will be followed for the duration of recovery from neuromuscular block, an expected average of 10min
|
Participants will be followed for the duration of recovery from neuromuscular block, an expected average of 10min
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
The time from start of sugammadex administration to recovery of the TOF ratio to 0.7 and 0.8.
Zeitfenster: Participants will be followed for the duration of recovery from neuromuscular block, an expected average of 10min
|
Participants will be followed for the duration of recovery from neuromuscular block, an expected average of 10min
|
Adverse hemodynamic events.
Zeitfenster: From anesthesia induction until 3h after arrival in the postanaesthesia care unit (PACU).
|
From anesthesia induction until 3h after arrival in the postanaesthesia care unit (PACU).
|
Adverse respiratory events (SpO2 <90% and/or signs of airway obstruction).
Zeitfenster: From arrival in the PACU until 30min thereafter.
|
From arrival in the PACU until 30min thereafter.
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Guy Cammu, MD, PhD, OLV Hospital, Anesthesiology and CCM, Aalst, Belgium
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Staals LM, Snoeck MM, Driessen JJ, Flockton EA, Heeringa M, Hunter JM. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. Br J Anaesth. 2008 Oct;101(4):492-7. doi: 10.1093/bja/aen216. Epub 2008 Jul 23.
- Dahl V, Pendeville PE, Hollmann MW, Heier T, Abels EA, Blobner M. Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. Eur J Anaesthesiol. 2009 Oct;26(10):874-84. doi: 10.1097/EJA.0b013e32832c605b.
- Sorgenfrei IF, Norrild K, Larsen PB, Stensballe J, Ostergaard D, Prins ME, Viby-Mogensen J. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology. 2006 Apr;104(4):667-74. doi: 10.1097/00000542-200604000-00009.
- Suzuki T, Kitajima O, Ueda K, Kondo Y, Kato J, Ogawa S. Reversibility of rocuronium-induced profound neuromuscular block with sugammadex in younger and older patients. Br J Anaesth. 2011 Jun;106(6):823-6. doi: 10.1093/bja/aer098. Epub 2011 Apr 29.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- B126201112363
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Postoperative neuromuskuläre Blockade
-
University of TriesteCliniche Humanitas Gavazzeni; A.O.U. Città della Salute e della Scienza - Molinette...UnbekanntSchmerzen, postoperativ | SAP-Block versus ESP-Block | Bewertung lokoregionaler Techniken | Multimodale SchmerztherapieItalien
-
Kangbuk Samsung HospitalUnbekanntSchmerzen, postoperativ | Regionaler BlockKorea, Republik von
-
Minia UniversityAbgeschlossenPostoperative Schmerzen | Regionaler BlockÄgypten
-
Bruce Ben-DavidZurückgezogenPostoperative Schmerzen | Analgesie | BlockVereinigte Staaten
-
Universidade Federal do Rio de JaneiroAbgeschlossenSchmerzen, postoperativ | Motorik | Faszikulärer Block | Latenzzeit
-
Tanta UniversityNoch keine RekrutierungInterskalenärer Block | Oberflächlicher zervikaler BlockÄgypten
-
Minia UniversityRekrutierungPostoperative Schmerzen | Regionaler BlockÄgypten
-
Medical University of South CarolinaAbgeschlossenPostoperative Schmerzen | Hüftersatz | BlockVereinigte Staaten
-
Centre hospitalier de l'Université de Montréal...AbgeschlossenSpinalanästhesie | Längerer sensorischer Block | Längerer motorischer BlockKanada
-
Aydin Adnan Menderes UniversityUnbekanntErector-Spinae-BlockTruthahn
Klinische Studien zur Sugammadex
-
University Health Network, TorontoMerck Sharp & Dohme LLCAbgeschlossenPosteriore zervikale Dekompression und FusionKanada
-
Seoul National University HospitalRekrutierungPostoperative RestkurarisierungKorea, Republik von
-
Wake Forest University Health SciencesMerck Sharp & Dohme LLCRekrutierungPostoperativer HarnverhaltVereinigte Staaten
-
Severance HospitalAbgeschlossenErholungsphase der Anästhesie, neuromuskuläre BlockadeKorea, Republik von
-
Merck Sharp & Dohme LLCAbgeschlossenNiereninsuffizienz | NierenfunktionsstörungVereinigte Staaten
-
Fondazione Policlinico Universitario Agostino Gemelli...AbgeschlossenProstatakrebs | Neuromuskuläre BlockadeItalien
-
Hopital FochAbgeschlossen
-
Beijing Tiantan HospitalAbgeschlossenSugammadex | Motorisch evozierte PotentialeChina
-
Merck Sharp & Dohme LLCAbgeschlossen
-
Technical University of MunichAbgeschlossenNeuromuskuläre BlockadeDeutschland